Pleasanton, California
United States
57
2026-06-04
The entities that hold a legal rights for patent applications filed by inventor Chen Yi:
Yi Chen from Pleasanton, US has applied for patents for these inventions. The list has both pending applications and granted patents:
BCL-2 INHIBITORS
#2 | 2026-04-23TRANSGLUTAMINASE TREATED PRODUCTS
#3 | 2026-01-15MDM2 DEGRADER
#4 | 2025-09-18METHOD FOR ENZYMATIC TREATMENT OF TISSUE PRODUCTS
#5 | 2025-06-05CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES
#6 | 2025-05-08MUTANT KRAS MODULATORS AND USES THEREOF
#7 | 2025-05-01BTK DEGRADER
#8 | 2025-04-24ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF
#9 | 2025-04-10BCL-2 INHIBITORS
#10 | 2025-03-27BCL-2 INHIBITORS
#11 | 2025-03-06SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF
#12 | 2025-02-13BCL-2 INHIBITORS
#13 | 2025-02-06INHIBITORS OF BTK AND MUTANTS THEREOF
#14 | 2024-12-26BCL-2 INHIBITORS
#15 | 2024-11-28INHIBITOR OF BTK AND MUTANTS THEREOF
#16 | 2024-07-04QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS
#17 | 2024-06-06BCL-2 INHIBITORS
#18 | 2024-05-231H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES
#19 | 2024-02-22BTK DEGRADER
#20 | 2023-11-30INHIBITORS OF BTK
#21 | 2023-11-16TRANSGLUTAMINASE TREATED PRODUCTS
#22 | 2023-11-02DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF
#23 | 2023-09-21HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR
#24 | 2023-08-31CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES
#25 | 2023-05-04Substituted pyrazines as inhibitors of BTK, and mutants thereof
#26 | 2023-04-201H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES
#27 | 2023-03-23QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS
#28 | 2022-12-22BCL-2 inhibitors
#29 | 2022-11-24CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS
#30 | 2022-11-17INHIBITOR OF BTK AND MUTANTS THEREOF
#31 | 2022-07-21SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS
#32 | 2022-07-14Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
#33 | 2022-05-05INHIBITOR OF BTK AND MUTANTS THEREOF
#34 | 2022-03-101H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES
#35 | 2021-10-28BCL-2 inhibitors
#36 | 2021-10-14BCL-2 inhibitors
#37 | 2021-06-10BCL-2 INHIBITORS
#38 | 2021-03-04Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
#39 | 2021-01-21Transglutaminase treated products
#40 | 2020-12-03Substituted pyrazines as inhibitors of BTK, and mutants thereof
#41 | 2020-09-24COVALENT INHIBITORS OF CDK-7
#42 | 2020-07-30MESH COMPOSITIONS AND METHODS OF PRODUCTION
#43 | 2020-07-16NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION
#44 | 2020-06-25BCL-2 inhibitors
#45 | 2020-06-18Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases
#46 | 2020-03-05BCL-2 INHIBITORS
#47 | 2019-12-12Transglutaminase treated products
#48 | 2019-06-06Therapeutic agents for the treatment of HBV infection
#49 | 2019-05-23METHOD FOR ENZYMATIC TREATMENT OF TISSUE PRODUCTS
#50 | 2019-05-23Covalent inhibitors of CDK-7
#51 | 2019-02-07BCL-2 inhibitors
#52 | 2018-06-21Therapeutic agents for the treatment of HBV infection
#53 | 2018-01-11Covalent inhibitors of CDK-7
#54 | 2017-10-26Dual-warhead covalent inhibitors of FGFR-4
#55 | 2016-07-28INHIBITORS OF BRUTON'S TYROSINE KINASE
#56 | 2015-03-26Therapeutic agents
#57 | 2013-10-24HDAC inhibiting derivatives of camptothecin
498555 ⎘